Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for approval of darolutamide (Nubeqa) for treatment of prostate cancer

Darolutamide is an androgen receptor inhibitor that binds directly to the receptor ligand binding domain and will be available as 300mg film-coated tablets.

Source:

European Medicines Agency